Organisation paid for research Program year 2025 Source: CMS Open Payments

Retina Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$216,313

16 payments

Through program year 2025, Retina Associates LLC is reported as receiving $216,313 in research payments, across 16 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$62,188	13
2024	Research	$154,126	3

Breakdown

Who paid Research payments · program years 2024–2025

EyePoint Pharmaceuticals US, Inc. $154,126 3 payments
ANI Pharmaceuticals, Inc. $35,905 5 payments
AbbVie, Inc. $26,282 8 payments

Studies the money was for Research payments · program years 2024–2025

A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) $83,894 1 payment
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $55,932 1 payment
New Day Study $35,905 5 payments
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $14,300 1 payment
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) $11,162 1 payment
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) $6,120 1 payment
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy $5,141 1 payment
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) $3,860 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.